NCT04783636View on ClinicalTrials.gov

To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

July 20, 2021

Study Completion Date

July 20, 2021

Conditions
Prostate Cancer
Interventions
DRUG

leuprorelin acetate 3.75mg

PT105, PT105R

Sponsors

Lead Sponsor

Peptron, Inc.
All Listed Sponsors
lead

Peptron, Inc.

INDUSTRY

NCT04783636 - To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers | Biotech Hunter | Biotech Hunter